Shares of BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) shot up 1.4% during trading on Friday . The stock traded as high as $2.97 and last traded at $2.91, with a volume of 179,485 shares trading hands. The stock had previously closed at $2.87.

Several brokerages recently commented on BCRX. Zacks Investment Research lowered BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, May 9th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Monday, May 9th. Jefferies Group upgraded BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a research report on Wednesday, June 1st. Finally, FBR & Co reiterated a “buy” rating and issued a $6.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Wednesday, July 6th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the company. BioCryst Pharmaceuticals currently has an average rating of “Hold” and an average target price of $9.70.

The company’s market capitalization is $218.13 million. The company has a 50 day moving average price of $3.11 and a 200 day moving average price of $3.90.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Thursday, May 5th. The biotechnology company reported ($0.31) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.23) by $0.08. During the same quarter in the previous year, the company posted ($0.21) earnings per share. The business earned $4.82 million during the quarter, compared to analysts’ expectations of $5.42 million. The business’s quarterly revenue was down 29.4% on a year-over-year basis. Equities analysts anticipate that BioCryst Pharmaceuticals Inc. will post ($1.06) EPS for the current year.

Other large investors have modified their holdings of the company. Globeflex Capital L P acquired a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter worth $1,241,000. Morgan Stanley increased its stake in shares of BioCryst Pharmaceuticals by 13.9% in the fourth quarter. Morgan Stanley now owns 103,804 shares of the biotechnology company’s stock worth $1,071,000 after buying an additional 12,646 shares in the last quarter. Finally, Jennison Associates LLC increased its stake in shares of BioCryst Pharmaceuticals by 1.8% in the fourth quarter. Jennison Associates LLC now owns 1,348,563 shares of the biotechnology company’s stock worth $13,917,000 after buying an additional 24,014 shares in the last quarter.

BioCryst Pharmaceuticals, Inc (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and advanced chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.